Core Viewpoint - Merck's pneumonia vaccine demonstrated strong immune responses in children and teens at higher risk of serious illness, based on late-stage study results [1] Company Summary - Merck announced the positive results of its pneumonia vaccine, indicating its effectiveness in generating immune responses among vulnerable populations [1] Industry Summary - The findings from Merck's study could have significant implications for the vaccine market, particularly in addressing pneumonia in high-risk groups [1]